Swissmedic Health Advertising: How to Review Pharmaceutical and Medical Device Marketing in Switzerland

Swissmedic, the Swiss Agency for Therapeutic Products, regulates the advertising of medicinal products and medical devices in Switzerland under the Therapeutic Products Act (TPA, Heilmittelgesetz) and its implementing ordinances. Switzerland is not an EU member, which means EU pharmaceutical advertising directives do not automatically apply — Swissmedic maintains its own standards that share principles with EU law but have distinct Swiss requirements.

Swissmedic has robust enforcement powers, including the authority to order advertising cessation, require corrective communications, impose financial penalties, and — in serious cases — refer matters for criminal prosecution. For pharmaceutical companies, medical device manufacturers, and healthcare organizations operating in the Swiss market, every piece of promotional content must comply with the TPA framework.

The Regulatory Framework

Key Regulations

The Public vs. Professional Distinction

Swiss pharmaceutical advertising law makes a fundamental distinction:

Public advertising (Publikumswerbung):

• Permitted only for OTC (non-prescription) medicinal products in categories A (subject to medical prescription — prohibited), B (prescription-only — prohibited), C (pharmacist dispensing — permitted with restrictions), D (drugstore dispensing — permitted), and E (general sale — permitted)
• Must include specific mandatory information
• Subject to pre-clearance requirements for certain product categories

Professional advertising (Fachwerbung):

• Permitted for all authorized medicinal products including prescription drugs
• Directed exclusively to healthcare professionals authorized to prescribe, dispense, or use the products
• Must be based on the approved product information (Arzneimittelinformation)
• Subject to Pharma Code self-regulatory requirements

Common Health Advertising Compliance Issues

1. OTC Drug Public Advertising

Public advertising for OTC drugs must include:

• Product name and active substance
• Indication for use (matching the approved label)
• Mandatory advisory: "Dies ist ein zugelassenes Arzneimittel. Lesen Sie die Packungsbeilage" (This is an authorized medicinal product. Read the package insert) or the equivalent in French/Italian
• Name of the marketing authorization holder
• No claims beyond the approved indications
• No disease-specific fear appeals
• No suggestions that the product is without risk or side effects

2. Prescription Drug Boundaries

Advertising prescription drugs to the public is prohibited. Common boundary violations include:

• Disease awareness campaigns that effectively promote a specific prescription product
• Patient support programs that cross the line into promotional activity
• Social media content from pharmaceutical companies that references prescription products
• News releases about clinical trial results directed at the general public

3. Medical Device Advertising

Under the MedDO (aligned with the EU MDR framework), medical device advertising must:

• Reference only the intended use as defined in the conformity assessment
• Not claim performance beyond what is certified
• Include the conformity marking (CE marking recognized in Switzerland under mutual recognition)
• Provide risk disclosures appropriate to the device classification
• Not use testimonials suggesting guaranteed outcomes

4. Complementary and Traditional Medicine

Switzerland has a unique regulatory framework for complementary medicine (homeopathy, anthroposophic medicine, traditional Chinese medicine), which is partially covered by mandatory health insurance. Advertising for these products:

• Must not claim equivalence to conventional medicinal products
• Must be labeled as complementary/traditional medicine
• Must comply with TPA advertising requirements if they hold a Swissmedic authorization
• Cannot make disease cure claims without evidence meeting Swissmedic standards

A Health Advertising Content Review Checklist

• Product has valid Swissmedic marketing authorization
• Claims match the approved product information (Arzneimittelinformation)
• No public advertising for prescription-only (Category A/B) products
• OTC public ads include mandatory "read the package insert" advisory
• Product name, active substance, and marketing authorization holder are stated
• No claims beyond approved indications
• No suggestion that the product is risk-free
• Disease awareness campaigns do not implicitly promote a specific Rx product
• Medical device advertising references only the certified intended use
• Conformity marking is correctly displayed
• Complementary medicine is labeled appropriately
• Professional advertising is directed exclusively to authorized HCPs
• Content is available in German, French, and Italian as appropriate
• Pharma Code self-regulatory requirements are met for HCP-directed content
• No gifts or incentives violating TPA restrictions

Building a Health Advertising Review Process

Organizations marketing health products in Switzerland should implement:

1. Product classification: Determine the dispensing category (A-E) and applicable advertising rules
2. Audience verification: Confirm whether content is directed at the public or healthcare professionals
3. Label cross-check: Verify all claims against the approved Arzneimittelinformation
4. Pre-publication review: AI-assisted scanning for label compliance, missing mandatory statements, and audience boundary issues
5. Multi-language review: Ensure German, French, and Italian versions are compliant and consistent
6. Swissmedic submission: Submit for pre-clearance where required

TeamBench enables healthcare organizations to build Swissmedic-specific content reviewers that evaluate health advertising against Swiss therapeutic product standards. Custom criteria can check label compliance, mandatory statement presence, audience boundary adherence, and multi-language consistency — catching violations before they reach the market.

In Switzerland's multilingual, highly regulated health market, systematic content review ensures that the speed of marketing does not outpace the rigor of compliance.